Announcements Trials

Browse Landscape

Sponsor

Conditions

Nasopharyngeal Carcinoma 3 Colorectal Neoplasms 3 Carcinoma, Renal Cell 3 Carcinoma, Non-Small-Cell Lung 3 Uterine Cervical Neoplasms 2 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Prostatic Neoplasms 2 Melanoma 2 Endometrial Neoplasms 2 Solid Tumors 1 Sarcoma 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Nasopharangeal Cancer 1 Lymphoma, T-Cell, Peripheral 1 Lung Neoplasms 1 Kidney Neoplasms 1 Kidney Diseases 1 Hemangiosarcoma 1 Glioma 1 Glioblastoma 1 Fibrolamellar hepatocellular carcinoma 1 Esophageal Squamous Cell Carcinoma 1 Diffuse Intrinsic Pontine Glioma 1 CRC 1

Interventions

Nivolumab 2 trametinib 1 selpercatinib 1 lenvatinib 1 fludarabine 1 dabrafenib 1 cemiplimab 1 aldesleukin 1 Radiotherapy, Intensity-Modulated 1 Ipilimumab 1 Cyclophosphamide 1 CTLA-4 Antigen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

0 trials

Recent Start date Enrollment

Thyroid Carcinoma, Anaplastic × spartalizumab × 90 days × Clear all

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡